TGFB1 and schistosomiasis: In support of our findings, cellular therapy of monocytes (CD14+ CD11b+) contributes to tissue remodeling, reduces the production of TGF-β and upregulates Fizz1 (M2 marker) expression in the liver during experimental schistosomiasis (37).